

Press Release

June 12, 2023

Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

New Launch of Mounjaro® 7.5 mg /10 mg /12.5 mg /15 mg Ateos®, the World's First Sustained Release GIP/GLP-1 Receptor Agonist Full Lineup Now Available

June 12, 2023 - Eli Lilly Japan K.K. (Head Office: Kobe, Japan, Representative Director and President: Simone Thomsen, hereinafter called “Eli Lilly Japan”) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan, Representative Director: Akihiro Tsujimura, hereinafter called “MTPC”) announced that “Mounjaro® subcutaneous injection 7.5 mg /10 mg /12.5 mg /15 mg ATEOS®” (Non-proprietary name: Tirzepatide, hereinafter referred called “Mounjaro”), the following sustained release GIP/GLP-1 receptor agonists, was launched in Japan today.

Of the six dosage standards for the Mounjaro® subcutaneous injection, two were launched ahead of time on April 18 this year, namely, the starting dose (2.5 mg) and the maintenance dose (5 mg). However, on this occasion, Eli Lilly Japan and MTPC have now added the remaining four higher dose standards (7.5 mg, 10 mg, 12.5 mg, and 15 mg) to complete the Mounjaro lineup.



As the world's first sustained release GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Mounjaro activates two receptors: GIP and GLP-1. Although the structure of Mounjaro is a single molecule based on the natural GIP peptide sequence, it has been modified to also bind to the GLP-1 receptor, and selectively acts for a long time to improve blood glucose.

Mounjaro is administered once weekly by subcutaneous injection with a single-use autoinjector device (ATEOS). Using a special pen injector with a pre-installed needle, the needle is automatically inserted

under the skin by pressing the injection button, and a single dose of the filled drug is injected. The patient does not need to set the dose or handle the needle.

For adults, the drug tirzepatide is usually used with a starting dose of 2.5 mg once a week administered for 4 weeks, and then increased to a maintenance dose of 5 mg once a week. It is a drug whose dosage can be increased or decreased according to each patient's condition, and if the efficacy of 5 mg is insufficient, the dose can be increased in 2.5 mg increments at intervals of 4 weeks or more, and up to 15 mg can be used once a week.

Eli Lilly Japan holds the manufacturing and marketing approval for Mounjaro, while MTPC is responsible for sales and distribution. Eli Lilly Japan and MTPC will jointly provide information to healthcare professionals. Through this product lineup, both Eli Lilly Japan and MTPC will strive to provide appropriate information so that both companies can contribute to improving the lives of people living with type 2 diabetes mellitus.

Reference Information

Product Summary

Product Name	Mounjaro® subcutaneous injection 7.5 mg ATEOS® Mounjaro® subcutaneous injection 10 mg ATEOS® Mounjaro® subcutaneous injection 12.5 mg ATEOS® Mounjaro® subcutaneous injection 15 mg ATEOS®
Non-proprietary Name	Tirzepatide
Indications	Type 2 diabetes
Dosage and Administration	For adults, the usual maintenance dose of Tirzepatide is 5 mg once a week by subcutaneous injection. However, start with 2.5 mg once weekly and increase to 5 mg once weekly after 4 weeks. The dosage may be adjusted according to the patient's condition, but if the effect is insufficient with 5 mg once a week, the dosage can be increased by 2.5 mg at intervals of 4 weeks or longer. However, the maximum dosage should be up to 15 mg once weekly.
Date of acquisition of manufacturing and marketing approval	September 26, 2022
Date of NHI price listing	March 15, 2023
Date of launch	June 12, 2023
Drug price	Mounjaro® subcutaneous injection 7.5 mg ATEOS® 0.5mL 1kit: 5,772 yen Mounjaro® subcutaneous injection 10 mg ATEOS® 0.5mL 1kit: 7,696 yen Mounjaro® subcutaneous injection 12.5 mg ATEOS® 0.5mL 1kit: 9,620 yen Mounjaro® subcutaneous injection 15 mg ATEOS® 0.5mL 1kit: 11,544 yen
Manufacturer and distributor	Eli Lilly Japan K.K.
Distributor	Mitsubishi Tanabe Pharma Corporation

Product Pictures



Mounjaro® subcutaneous injection 7.5 mg ATEOS



Mounjaro® subcutaneous injection 10 mg ATEOS



Mounjaro® subcutaneous injection 12.5 mg ATEOS



Mounjaro® subcutaneous injection 15 mg ATEOS

About Eli Lilly Japan

Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical treatment in Japan through the development, manufacture, import and sale of innovative pharmaceutical products that enable people to live longer, healthier, and more fulfilling lives, focusing on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous system diseases, autoimmune diseases, growth disorder, and pain. For more information, visit <http://www.lilly.co.jp>

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to <https://www.mt-pharma.co.jp/e/>